Ozanimod showed a rapid onset of action and efficacy as extended induction therapy in patients with ulcerative colitis nonresponsive to biologics.

Recommendation based on the findings from the Phase 3 QUASAR programme in ulcerative colitis 1. Beerse, Belgium (28 February 2025) - Johnson & Johnson today announced that the Com ...

For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

The risk for both self-reported and symptomatic flare in inflammatory bowel disease is associated with psychosocial factors, ...

They dance in kitchens and in meadows frothy with flowers. They dance at weddings. They dance while fireworks bloom in dark ...